Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Biochemistry Underlying the Cardiac Calcium Cycle; Regulation of SERCA by Phsospholamban
EF 2013-14
Résumé
Heart disease remains the number one human health risk. Yet despite a bewildering array of root causes for heart disease, calcium transport proteins have been identified as drug targets for improved clinical outcomes. The Young lab has set out to probe the fundamental molecular mechanisms involved in critical calcium homeostasis pathways in normal and disease-associated cardiovascular function. The main research theme is to understand the structure and mechanism of endogenous regulatory complexes that control the relationship between sarcoplasmic reticulum (SR) calcium stores and cardiac muscle relaxation. Mutations in genes responsible for SR calcium transport are associated with cardiac hypertrophy, cardiomyopathy and arrhythmia.
It is well-established that the dynamic movement of calcium stores is essential for excitation-contraction coupling and normal cardiovascular function, and that dysregulation of calcium homeostasis is causative in many forms of heart disease. Phospholamban is a small protein that regulates the calcium pump SERCA and it is known to be susceptible to mutations in hereditary dilated cardiomyopathy (DCM). The Young lab has been involved in a detailed mechanistic study of the known disease-causing mutations in Phospholamban. They have discovered a novel mutation in Phospholamban (Arg9-to-Leu) that mimicked a severe hereditary mutation found in patients (Arg9-to-Cys). They predicted that this novel mutation would be found in heart failure patients, and two such patients were found in a Brazilian study. To the best of my knowledge, this is the first time that a specific mutation in PLN was predicted to be associated with severe DCM. The strong clinical relevance of this research provides a potential for application of the discoveries made in this area. The intention of my project is to establish a more extensive prediction model for Phospholamban mutations that may be associated with heart failure, by combining structural information of how these two proteins are regulated and how this effects their function.
The Young lab is currently sequencing the Phospholamban gene in ~1000 patients that are part of an Acute Heart Failure study (Dr. Justin Ezekowitz, University of Alberta Hospital). The goal is to establish the prevalence of mutations in Phospholamban in Alberta heart failure patients, for the first time. Genome sequencing efforts (e.g. 1000 Genomes Project, COSMIC database) have revealed twelve mutations in the human phospholamban gene, however only three of these mutations have been characterized and linked to heart failure. With this in mind, I will explore the following areas with the overall goal of combining clinical relevance with state of the art structural biology.
Aim one – A major goal of my research project is to have a direct linkage to patient outcomes. To achieve this, I will be involved in sequencing the PLN gene in heart failure patients (along with a Research Associate in the Young lab, Dr. Catharine Trieber).
Aim two – My plan is to generate all known disease-causing PLN mutants and to probe the detailed mechanism by which these mutants regulate SERCA using membrane reconstitution, biochemical activity and phosphorylation assays, kinetic simulations and molecular modeling. I will develop a molecular understanding of why these particular mutants are associated with disease and I will establish a prediction model for additional mutations that may be found in the human population.
Aim three – I will determine the structure of the SERCA-Phospholamban inhibitory complex using the techniques of electron cryo-microscopy (cryo-EM). The immediate objective is a molecular description of the interactions of SERCA with disease-associated mutants of PLN.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
311712
Name
Armanious Gareth P
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Biochemistry Underlying the Cardiac Calcium Cycle; Regulation of SERCA by Phsospholamban
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Activity; Biochemistry; Cardiomyopathy; Cardiovascular Disease; Phospholamban; Proteoliposome; Sarcolipin; Serca
Abstract
Heart disease remains the number one human health risk. Yet despite a bewildering array of root causes for heart disease, calcium transport proteins have been identified as drug targets for improved clinical outcomes. The Young lab has set out to probe the fundamental molecular mechanisms involved in critical calcium homeostasis pathways in normal and disease-associated cardiovascular function. The main research theme is to understand the structure and mechanism of endogenous regulatory complexes that control the relationship between sarcoplasmic reticulum (SR) calcium stores and cardiac muscle relaxation. Mutations in genes responsible for SR calcium transport are associated with cardiac hypertrophy, cardiomyopathy and arrhythmia.
It is well-established that the dynamic movement of calcium stores is essential for excitation-contraction coupling and normal cardiovascular function, and that dysregulation of calcium homeostasis is causative in many forms of heart disease. Phospholamban is a small protein that regulates the calcium pump SERCA and it is known to be susceptible to mutations in hereditary dilated cardiomyopathy (DCM). The Young lab has been involved in a detailed mechanistic study of the known disease-causing mutations in Phospholamban. They have discovered a novel mutation in Phospholamban (Arg9-to-Leu) that mimicked a severe hereditary mutation found in patients (Arg9-to-Cys). They predicted that this novel mutation would be found in heart failure patients, and two such patients were found in a Brazilian study. To the best of my knowledge, this is the first time that a specific mutation in PLN was predicted to be associated with severe DCM. The strong clinical relevance of this research provides a potential for application of the discoveries made in this area. The intention of my project is to establish a more extensive prediction model for Phospholamban mutations that may be associated with heart failure, by combining structural information of how these two proteins are regulated and how this effects their function.
The Young lab is currently sequencing the Phospholamban gene in ~1000 patients that are part of an Acute Heart Failure study (Dr. Justin Ezekowitz, University of Alberta Hospital). The goal is to establish the prevalence of mutations in Phospholamban in Alberta heart failure patients, for the first time. Genome sequencing efforts (e.g. 1000 Genomes Project, COSMIC database) have revealed twelve mutations in the human phospholamban gene, however only three of these mutations have been characterized and linked to heart failure. With this in mind, I will explore the following areas with the overall goal of combining clinical relevance with state of the art structural biology.
Aim one – A major goal of my research project is to have a direct linkage to patient outcomes. To achieve this, I will be involved in sequencing the PLN gene in heart failure patients (along with a Research Associate in the Young lab, Dr. Catharine Trieber).
Aim two – My plan is to generate all known disease-causing PLN mutants and to probe the detailed mechanism by which these mutants regulate SERCA using membrane reconstitution, biochemical activity and phosphorylation assays, kinetic simulations and molecular modeling. I will develop a molecular understanding of why these particular mutants are associated with disease and I will establish a prediction model for additional mutations that may be found in the human population.
Aim three – I will determine the structure of the SERCA-Phospholamban inhibitory complex using the techniques of electron cryo-microscopy (cryo-EM). The immediate objective is a molecular description of the interactions of SERCA with disease-associated mutants of PLN.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Armanious, Gareth P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~